Improved harmonization of eosin‐5‐maleimide binding test across different instruments and age groups

Agarwal, Archana; Liew, Michael; Nussenzveig, Roberto; Sangle, Nikhil; Heikal, Nahla; Yaish, Hassan M.; Christensen, Robert

doi:10.1002/cyto.b.21326

Cited by 9 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are still ongoing studies attempting to improve the utility of the EMA test. (43,46,53,61,62), while others use the mean fluorescence intensity obtained for EMAbound cells (63,64) or the EMA "footprint" (52,58). Despite these differences in presentation of EMA test results, it remains the most reliable screening test, with a relatively short time-around-time (TAT), high sensitivity, costeffectiveness and availability in laboratories equipped with even the most basic flow cytometer.…”

Section: Eosin-5'-maleimide Testmentioning

confidence: 99%

See 1 more Smart Citation

Old and new insights into the diagnosis of hereditary spherocytosis

Ciepiela¹

2018

Ann. Transl. Med.

View full text Add to dashboard Cite

Hereditary spherocytosis (HS) belongs to the group of congenital hemolytic anemias resulting from plasma membrane protein deficiency. When diagnosed too late, HS bares the risk of long-term complications including gall stones and severe anemia. Here, there are discussed advances in HS screening and diagnostics, with a particular focus on methodologies, most of which are available in clinical laboratories worldwide.

show abstract

Section: Eosin-5'-maleimide Testmentioning

confidence: 99%

“…, which is the position of EMA-bound RBCs in cytogram presenting side scatter versus EMA fluorescence channel, in order to allow better interpretation of the test(58). Finally Crisp et al demonstrated that a very small…”

mentioning

confidence: 99%

Old and new insights into the diagnosis of hereditary spherocytosis

Ciepiela¹

2018

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…The guideline for a diagnosis of HS by EMA-flow cytometry in newborns suggests using red cells from healthy term newborns as controls [1, 7, 16]. However, two previous studies have shown that the EMA-flow cytometry results obtained from healthy newborns or neonatal cord blood red cells are not significantly different to those from adult red cells [18, 19]. These findings suggest that red cells from adults can be used as controls for a newborn study.…”

Section: Resultsmentioning

confidence: 99%

Flow Cytometric Test with Eosin-5-Maleimide for a Diagnosis of Hereditary Spherocytosis in a Newborn

Fanhchaksai

Manowong

Natesirinilkul

et al. 2019

Case Reports in Hematology

View full text Add to dashboard Cite

A term male newborn born to a mother who had hereditary spherocytosis presented with neonatal jaundice at 20 hours of life. Complete blood count showed hemoglobin 17.1 g/dL, MCV 104.2 fL, MCH 32.9 pg, and MCHC 31.6 g/dL. The patient had indirect hyperbilirubinemia requiring phototherapy. The maximum total bilirubin level was 12.15 mg/dL at 20 hours of life. Peripheral blood smear revealed spherocytes, crenated red cells, and polychromasia. A flow cytometric test with eosin-5-maleimide- (EMA-) labeled RBC was performed in the patient and parents. The fluorescence histograms of EMA-labeled RBC from the patient and mother were shifted to the left, and the fluorescence ratio when compared with normal was 0.69 and 0.84, respectively. The flow cytometric test with EMA is useful in supporting the diagnosis of hereditary spherocytosis during newborn period.

show abstract

“…A flow cytometry‐based diagnosis of HS is still under research and development. Recently, Agarwal et al have published a paper that presents a new application of eosin‐5′‐maleimide test based on the analysis of EMA footprint, which indicates the position of EMA‐stained red blood cells in the cytogram with respect to EMA fluorescence and cells size (forward scatter). Similarly, a new test proposed by Won and Shu describes the flow cytometry‐based evaluation of osmotic fragility.…”

Section: Discussionmentioning

confidence: 99%

Flow cytometric osmotic fragility test: Increased assay sensitivity for clinical application in pediatric hematology

Ciepiela

Adamowicz-Salach

Zgodzińska

et al. 2017

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: Osmotic fragility test (OFT) is widely considered as a sensitive indicator of red blood cells' sensitivity to the hypotonic solution. It is often used as a screening test for the diagnosis of hereditary spherocytosis (HS). Nowadays, the osmotic fragility test based on flow cytometric analysis (FCM OF) is widely used in laboratory practice. The purpose of this study was to optimize the assay sensitivity and to validate its clinical application in the diagnostic screening of childhood anemias.Methods: The study was conducted on 175 children suffering from various types of anemia (including 30 children with proven hereditary spherocytosis, HS) and 16 healthy subjects. All children were aged between 3 months and 17 years, including 94 boys and 97 girls. FCM OF was performed on every subject according to two different analysis time patterns (hemolysis was analyzed for 214 or 300 s) using Cytomics FC500 flow cytometer.Results: Significant higher sensitivity was demonstrated by the tests carried out according to the longer analysis time pattern (90.0 vs. 83.33%). The level of specificity of both the analysis patterns was similar. When an extended analysis time was used, the percentage of red cell survival levels in HS patients were significantly lowered compared to the same cases analyzed with shorter incubation times and all other non-HS anemic cases (9.31 6 4.69 vs. 35.59 6 15.30%, P < 0.05). During the shorter analysis time, the values obtained were 13.76 6 7.92% for HS and 48.18 6 19.04% for non-HS, P < 0.0001. The 300-s test is very useful in distinguishing thalassemia patients from patients with other types of anemias (94.74% sensitivity and 90.12% specificity) and provided the values of remaining red blood cells as 70.46 6 12.29% for thalassemia and 27.16 6 13.01% for nonthalassemia subjects, P < 0.0001. Conclusion: Flow cytometric osmotic fragility test with a longer (300-s) analysis time demonstrated an increased sensitivity in detecting HS in anemic children. V C 2017 International Clinical Cytometry Society

show abstract

Improved harmonization of eosin‐5‐maleimide binding test across different instruments and age groups

Abstract: The inclusion of footprint parameter will help in better standardization as well as implementation of this test across different age groups as well as different instruments. © 2015 International Clinical Cytometry Society.

Cited by 9 publications

References 22 publications

Old and new insights into the diagnosis of hereditary spherocytosis

Old and new insights into the diagnosis of hereditary spherocytosis

Flow Cytometric Test with Eosin-5-Maleimide for a Diagnosis of Hereditary Spherocytosis in a Newborn

Flow cytometric osmotic fragility test: Increased assay sensitivity for clinical application in pediatric hematology

Contact Info

Product

Resources

About